Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bonneterre

Showing results (171-180 of 194) with videos related to

Pageof 20
Sort By:
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|March 1, 2011
[Intraoperative molecular assessment of sentinel nodes in the breast cancer using the Gene Search BLN Assay technique: our experience about 126 patients]J-L Houpeau, M-C Baranzelli, S Giard, et al.
European Journal of Cancer & Clinical Oncology|September 1, 1988
Presence and characterization of insulin-like growth factor 1 receptors in human benign breast diseaseJ P Peyrat, J Bonneterre, J C Laurent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2005
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group resultsP Fumoleau, H Roché, P Kerbrat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2005
Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study GroupM Campone, H Roché, P Kerbrat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 2006
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trialH Roché, P Kerbrat, J Bonneterre, et al.
British Journal of Cancer|August 1, 1996
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitorI Smith, A Jones, M Spielmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodesP Fumoleau, F Chauvin, M Namer, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2000
High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatmentS Kvinnsland, G Anker, L Y Dirix, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2000
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinomaP Rougier, A Adenis, M Ducreux, et al.
Anti-Cancer Drugs|August 13, 2002
Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumorsMaja J A de Jonge, B Glimelius, Jaap Verweij, et al.
Pageof 20

Showing results (171-180 of 194) with videos related to

Sort By:
Pageof 20
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|March 1, 2011
[Intraoperative molecular assessment of sentinel nodes in the breast cancer using the Gene Search BLN Assay technique: our experience about 126 patients]J-L Houpeau, M-C Baranzelli, S Giard, et al.
European Journal of Cancer & Clinical Oncology|September 1, 1988
Presence and characterization of insulin-like growth factor 1 receptors in human benign breast diseaseJ P Peyrat, J Bonneterre, J C Laurent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2005
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group resultsP Fumoleau, H Roché, P Kerbrat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2005
Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study GroupM Campone, H Roché, P Kerbrat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 2006
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trialH Roché, P Kerbrat, J Bonneterre, et al.
British Journal of Cancer|August 1, 1996
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitorI Smith, A Jones, M Spielmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodesP Fumoleau, F Chauvin, M Namer, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2000
High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatmentS Kvinnsland, G Anker, L Y Dirix, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2000
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinomaP Rougier, A Adenis, M Ducreux, et al.
Anti-Cancer Drugs|August 13, 2002
Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumorsMaja J A de Jonge, B Glimelius, Jaap Verweij, et al.
Pageof 20